Pharmacoeconomic analysis of paricalcitol and calcitriol in the treatment of secondary hyperparathyroidism in haemodialysis: Impact of hospitalisations and survival

Journal of Medical Economics

Volumn 10, Issue 4, 2007, Pages 393-409

  Schumock, Glen T ^a,d   Arruda, Jose A L ^b   Marx, Steven E ^c   Melnick, Joel ^c   Sterz, Raimund ^c   Williams, Laura A ^c  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF ILLINOIS   (United States)

^c ABBOTT LABORATORIES   (United States)

^d Center for Pharmacoeconomic Research   (United States)

Author keywords

Chronic renal failure; Cost effectiveness; Hyperparathyroidism

Indexed keywords

CALCITRIOL; PARICALCITOL;

ARTICLE; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; COST UTILITY ANALYSIS; DRUG COST; DRUG MECHANISM; HEMODIALYSIS; HOSPITAL COST; HOSPITALIZATION COST; HUMAN; MATHEMATICAL MODEL; OUTCOME ASSESSMENT; QUALITY ADJUSTED LIFE YEAR; SCORING SYSTEM; SECONDARY HYPERPARATHYROIDISM; SURVIVAL RATE;

EID: 38149138055     PISSN: 13696998     EISSN: None     Source Type: Journal    
DOI: 10.3111/13696990701646619     Document Type: Article

References (45)

1. U.S. Renal Data System. USRDS 2004 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2004.
2. Bricker NS, Slatopolsky E, Reiss E et al. Calcium, phosphorus and bone in renal disease and transplantation. Archives of Internal Medicine 1969; 123: 543-553.
3. De Boer IH, Gorodetskaya I, Young B et al. The severity of secondary hyperparathyroidism in chronic renal insufficiency is GFR-dependent, race-dependent, and associated with cardiovascular disease. Journal of the American Society of Nephrology 2002; 13: 2762-2769.
4. Sherrard DJ, Hercz G, Pei Y et al. The spectrum of bone disease in end-stage renal failure - an evolving disorder. Kidney International 1993; 43: 436-442.
5. Coco M, Rush H. Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone. American Journal of Kidney Diseases 2000; 36: 1115-1121.
6. Rix M, Andreassen H, Eskildsen P et al. Bone mineral density and biochemical markers of bone turnover in patients with predialysis chronic kidney failure. Kidney International 1999; 56: 1084-1093.
7. Tsuchihashi K, Takizawa H, Torii T et al. Hypoparathyroidism potentiates the cardiovascular complications through disturbed calcium metabolism. Possible risk of vitamin D analog administration in dialysis patients with end-stage renal disease. Nephron 2000; 84: 13-20.
8. Goodman W, Goldin J, Kuizon BD et al. Coronary artery calcification in young adults with end-stage renal disease who are undergoing dialysis. New England Journal of Medicine 2000; 342: 1478-1483.
9. Andress DL. Vitamin D in chronic kidney disease: a systemic role for selective vitamin D receptor activation. Kidney International 2006; 69: 33-43.
10. Silver J, Russell J, Sherwood LM. Regulation by vitamin D metabolites of messenger RNA for preparathyroid hormone in isolated bovine parathyroid cells. Proceedings of the National Academy of Sciences USA 1985; 82: 4270-4273.
11. Ramirez JA, Emmett M, White MG et al. The absorption of dietary phosphorus and calcium in hemodialysis patients. Kidney International 1986; 30: 753-759.
12. Block GA, Port FK. Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management. American Journal of Kidney Diseases 2000; 35: 1226-1235.
13. Finch JL, Brown AJ, Slatopolsky E. Differential effects of 1,25-dihydroxy-vitamin D3 and 19-nor-1,25-dihydroxy-vitamin D2 on calcium and phosphorus resorption in bone. Journal of the American Society of Nephrology 1999; 10: 980-985.
14. Brown AJ, Finch J, Slatopolsky E. Differential effects of 19-nor-1,25-dihydroxyvitamin D(2) and 1,25-dihydroxyvitamin D(3) on intestinal calcium and phosphate transport. Journal of Laboratory and Clinical Medicine 2002; 139: 279-284.
15. Martin K, Gonzalez E, Gellens M et al. 19-Nor-1-α-25- dihydroxyvitamin D2 (paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. Journal of the American Society of Nephrology 1998; 9: 1427-1432.
16. Goldenberg MM. Paricalcitol, a new agent for the management of secondary hyperparathyroidism in patients undergoing chronic renal dialysis. Clinical Therapeutics 1999; 21: 432-441.
17. Lindberg J, Martin KJ, Gonzalez EA et al. A long-term, multicenter study of the efficacy and safety of paricalcitol in end-stage renal disease. Clinical Nephrology 2001; 56: 315-323.
18. Slatopolsky E, Cozzolino M, Finch JL. Differential effects of 19-nor-1,25-(OH)(2)D(2) and 1alpha-hydroxyvitamin D(2) on calcium and phosphorus in normal and uremic rats. Kidney International 2002; 62: 1277-1284.
19. Nakane M, Fey TA, Dixon DB et al. Differential effects of vitamin D analogs on bone formation and resorption. Journal of Steroid Biochemistry and Molecular Biology 2006; 98: 72-77.
20. Teng M, Wolf M, Ofsthun N et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. Journal of the American Society of Nephrology 2005; 16: 1115-1125.
21. Dobrez DG, Mathes A, Amdahl M et al. Paricalcitol-treated patients experience improved hospitalization outcomes compared with calcitriol-treated patients in real-world clinical settings. Nephrology, Dialysis, Transplantation 2004; 19: 1174-1181.
22. Teng M, Wolf M, Lowrie E et al. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. New England Journal of Medicine 2003; 349: 446-456.
23. Sprague SM, Llach F, Amdahl M et al. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney International 2003; 63: 1483-1490.
24. Llach F, Yudd M. Paricalcitol in dialysis patients with calcitriol-resistant secondary hyperparathyroidism. American Journal of Kidney Diseases 2001; 38(Suppl. 5): S45-S50.
25. Mittman N, Khanna R, Rani S et al. Paricalcitol therapy for secondary hyperparathyroidism in patients on maintenance hemodialysis previously treated with calcitriol: a single-center crossover study. Kidney International Supplement 2006; (104): S64-S67.
26. Summary of 2005 Physician Schedule Final Rule. Available at: http://www.aapgpa.org/advocacy/1104_hpa_summary.pdf [accessed 7 June 2007].
27. 2006 The DRG Handbook. Comparative Clinical and Financial Benchmarks, Solucient, LLC.
28. Marx SE, Brown MD, Ashraf T et al. Evaluation of annualized dosing ratio of paricalcitol to calcitriol in hemodialysis patients. Journal of the American Society of Nephrology 2004; 15: 862A.
29. United States Department of Labor. Available at: http://www.bls.gov/ro5/ cpimpls.htm [accessed 17 October 2006].
30. Healthcare Cost & Utilization Project 2004 National Statistics - Principal Diagnosis Only. Available at: http://hcup.ahrq.gov/HCUPnet.jsp [accessed 16 October 2006].
31. Wolf M, Teng M, Thadhani R. Paricalcitol, calcitriol and survival of patients undergoing hemodialysis. New England Journal of Medicine 2003; 349: 1771-1772.
32. Berger ML, Bingefors K, Hedblom EC et al. Health care cost, quality, and outcomes. International Society for Pharmacoeconomics and Outcomes Research 2003; 241.
33. Eastman RC, Javitt JC, Herman WH. Model of complications of NIDDM. II. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia. Diabetes Care 1997; 20: 735-744.
34. Diabetes Control and Complications Trial Research Group. Lifetime benefits and costs of intensive therapy as practiced in the Diabetes Control and Complications Trial. Journal of the American Medical Association 1996; 276: 1409-1415.
35. Kiberd BA, Jindal KK. Screening to prevent renal failure in insulin dependent diabetic patients: an economic evaluation. British Medical Journal 1995; 311: 1595-1599.
36. Lawrence WF, Grist TM, Brazy PC. Magnetic resonance angiography in progressive renal failure: a technology assessment. American Journal of Kidney Diseases 1995; 25: 701-709.
37. Harvard CEA Registry. Standardizing the methods and practices of cost-effectiveness analysis. Available at: http://www.hcra.harvard.ede/pdf/ preferecescores.pdf [accessed 11 Feb 2005].
38. Robbins JD, Kim JJ, Zdon G et al. Resource use and patient care associated with chronic kidney disease in a managed care setting. Journal of Managed Care Pharmacy 2003; 9: 238-447.
39. United States Renal Data System. Cardiovascular report. Available at: http://www.usrds.org/adr.htm [accessed 20 May 2005].
40. St Peter WL, Khan SS, Ebben JP et al. Chronic kidney disease. The distribution of healthcare dollars. Kidney International 2004; 66: 313-321.
41. Drueke TB. Aspects of cardiovascular burden in pre-dialysis patients. Nephron 2000; 85(Suppl. 1): 9-14.
42. Capomolla S, Febo O, Ceresa M et al. Cost/utility ratio in chronic heart failure: comparison between heart failure management program delivered by day-hospital and usual care. Journal of the American College of Cardiology 2002; 40: 1259-1266.
43. Trentori F, Hunt WC, Stidley CA et al. Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney International 2006; 70: 1858-1856.
44. Kalantar-Zadeh K, Juwae N, Regidor DL et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney International 2006; 70: 771-780.
45. Drummond MF, Davies L. Economic analysis alongside clinical trials. Revisiting the methodological issues. International Journal of Technology Assessment in Health Care 1991; 7: 561-573.